Bevirimat

Bevirimat Struktur
174022-42-5
CAS-Nr.
174022-42-5
Englisch Name:
Bevirimat
Synonyma:
BVM;PA-457;CS-1322;MPC-4326;FH 11327;Bevirimat;Bevirimat, >99%;Bevirimat(PA-457);Bevirimat 174022-42-5;BVM; MPC-4326; PA-457
CBNumber:
CB22498801
Summenformel:
C36H56O6
Molgewicht:
584.83
MOL-Datei:
174022-42-5.mol

Bevirimat Eigenschaften

Schmelzpunkt:
>263°C (dec.)
Siedepunkt:
662.7±40.0 °C(Predicted)
Dichte
1.13±0.1 g/cm3(Predicted)
storage temp. 
Hygroscopic, -20°C Freezer, Under inert atmosphere
Löslichkeit
Acetonitrile (Slightly), Methanol (Very Slightly, Heated, Sonicated)
Aggregatzustand
Solid
pka
4.48±0.28(Predicted)
Farbe
White to Off-White
Stabilität:
Hygroscopic

Sicherheit

Bevirimat Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

PA-457 is an inhibitor of HIV-1 virion maturation. It inhibits the cleavage of the Gag capsid (CA) precursor CA-SP1 to the mature CA protein. PA-457 inhibits the replication of drug-sensitive and -resistant clinical isolates of HIV-1 in isolated human peripheral blood mononuclear cells (PBMCs; mean IC50s = 10.3 and 7.8 nM, respectively). In vivo, it prevents replication of HIV-1 in SCID-hu Thy/Liv mice when administered at a dose of 100 mg/kg.

Definition

ChEBI: A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhib tors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.

Enzyminhibitor

This first-in-class, natural product-based antiviral (FW = 584.83 g/mol; CAS 174022-42-5; Abbreviation: BVM), also known as 3-O-(3',3'- dimethylsuccinyl)betulinate (DSB), 3β-(3-carboxy-3-methyl-butanoyloxy)- lup-20(29)-en-28-oic acid, PA-457, and MPC-4326, is a novel HIV-1 maturation inhibitor that blocks proteolytic processing of the Gag capsid precursor (CA-SP1) into mature capsid (CA) protein. Bevirimat binds to the Gag polypeptide at the CA/SP1 cleavage site. The net result of BVM treatment is the release of immature, noninfectious viral particles. Despite its promising mode of action, about half of all patients have viruses containing genetic polymorphisms in the Gag SP1 (at positions 6 to 8) protein do not respond to BVM treatment.

Bevirimat Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Bevirimat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 114)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Hebei Mojin Biotechnology Co., Ltd
+86-13288715578 +8613288715578
sales@hbmojin.com China 12465 58
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3012 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3620 58
Chengdu Greenpure Biopharma CO.,Ltd
+8618283602253
jancyzheng@gcgreenpure.com China 952 58
Chengdu GLP biotechnology Co Ltd
028-87075086 13350802083
scglp@glp-china.com CHINA 1824 58
Chengdu Biopurify Phytochemicals Ltd.
+8618080483897
sales@biopurify.com China 3424 58
Hebei Guanlang Biotechnology Co., Ltd.
+86-19930503282
alice@crovellbio.com China 8829 58
Shaanxi Pioneer Biotech Co., Ltd .
+8613259417953
sales@pioneerbiotech.com China 3000 58
NanJing Spring & Autumn Biological Engineering CO., LTD.
+8613815430202
sale02@cqherb.com CHINA 376 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58

174022-42-5()Verwandte Suche:


  • Bevirimat
  • PA-457
  • FH 11327
  • O-(3,3-Dimethylsuccinyl)betulinic acid
  • Bevirimat(PA-457)
  • Bevirimat 174022-42-5
  • Bevirimat, PA 457, FH 312
  • CS-1322
  • MPC-4326
  • PA-457; MPC-4326; FH11327; YK FH312
  • Bevirimat, >99%
  • BVM
  • BVM; MPC-4326; PA-457
  • Lup-20(29)-en-28-oic acid, 3-(3-carboxy-3-methyl-1-oxobutoxy)-, (3β)-
  • 174022-42-5
Copyright 2019 © ChemicalBook. All rights reserved